文献速递系统性红斑狼疮

系统性红斑狼疮患者接种CoronaVac灭活SARS-CoV-2疫苗后异源加强针的免疫原性、安全性和反应原性:病例系列

Immunogenicity, safety and reactogenicity of a heterogeneous booster following the CoronaVac inactivated SARS-CoV-2 vaccine in patients with SLE: a case series.
PubMed 文献 · RMD Open · 2021-01-01

该病例系列描述了系统性红斑狼疮(SLE)患者在完成CoronaVac灭活SARS-CoV-2疫苗基础免疫后,接种异源加强针(mRNA或病毒载体疫苗)的安全性和免疫原性。研究发现,在维持免疫抑制治疗未中断的非活动性SLE患者中,第三剂异源加强针耐受良好,并引发了实质性的体液和细胞免疫应答。

要点

  • 在维持免疫抑制治疗未中断的非活动性SLE患者中,异源第三剂加强针耐受良好。
  • 异源加强针引发了实质性的体液和细胞免疫应答。
  • 研究结果支持在初始CoronaVac灭活疫苗系列后接种mRNA或病毒载体疫苗作为第三剂加强针。

核心结论

  • 在初始CoronaVac灭活疫苗系列后接种mRNA或病毒载体疫苗的第三剂加强针耐受良好,并在维持免疫抑制治疗未中断的非活动性SLE患者中引发了实质性的体液和细胞免疫应答。

研究设计与样本

  • 病例系列,描述系统性红斑狼疮(SLE)患者在初始CoronaVac灭活疫苗系列后接受异源SARS-CoV-2疫苗加强针的安全性、反应原性和免疫原性。

主要发现

  • 第三剂mRNA或病毒载体疫苗加强针耐受良好,并引发了实质性的体液和细胞免疫应答。
  • 该结果见于维持免疫抑制治疗未中断的非活动性SLE患者。

临床怎么用

  • 研究结果支持在初始CoronaVac灭活疫苗系列后接种mRNA或病毒载体疫苗作为第三剂加强针。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Since the COVID-19 pandemic, CoronaVac, an inactivated SARS-CoV-2 vaccine, has been widely deployed in several countries for emergency use. However, the immunogenicity of the inactivated vaccine was relatively lower when compared to other vaccine types and was even more attenuated in autoimmune patients with rheumatic disease. A third-dose SARS-CoV-2 vaccination in immunosuppressed population is recommended in order to improve immune response. However, the data were limited to those initially received mRNA or viral vector SARS-CoV-2 vaccine. Thus, we aimed to describe the safety, reactogenicity and immunogenicity of patients with systemic lupus erythematosus (SLE) who received a heterogenous booster SARS-CoV-2 vaccine following the initial CoronaVac inactivated vaccine series. Our findings support that the third booster dose of mRNA or viral vector vaccine following the inactivated vaccine is well tolerated and elicited a substantial humoral and cellular immune response in inactive patients with SLE having maintenance immunosuppressive therapy without interruption of immunosuppressive medications.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Assawasaksakul T, Sathitratanacheewin S, Vichaiwattana P, et al. Immunogenicity, safety and reactogenicity of a heterogeneous booster following the CoronaVac inactivated SARS-CoV-2 vaccine in patients with SLE: a case series. RMD Open. 2021. PMID: 34862313. doi:10.1136/rmdopen-2021-002019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。